News Channels

14 Jun 2017 ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
14 Jun 2017 Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
14 Jun 2017 Pimodivir Alone or in Combination with Oseltamivir Demonstrated a Significant Reduction in Viral Load in Adults with Influenza A
14 Jun 2017 Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model
14 Jun 2017 Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients
14 Jun 2017 Phase 1 Clinical Study Results of REMD Biotherapeutics’ Lead Product Candidate, REMD-477, Demonstrate Reduced Need for Insulin and Improved Blood Glucose Levels for Patients with Type 1 Diabetes
14 Jun 2017 Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain
14 Jun 2017 Domainex expands partnership with Imperial College London to reduce heart muscle damage during heart attacks
13 Jun 2017 New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation
13 Jun 2017 InMed Announces Agreement to Advance a Topical Formulation of INM-750
13 Jun 2017 Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.
13 Jun 2017 ENYO Pharma SA Announces Successful Completion of EYP001 First in Man Phase 1 Study
13 Jun 2017 FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy
13 Jun 2017 New LEADER analysis shows Victoza® reduces cardiovascular risk in people with type 2 diabetes regardless of severe hypoglycaemia events
13 Jun 2017 Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab
13 Jun 2017 AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors
13 Jun 2017 Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
13 Jun 2017 Merck Provides Update on Multiple Myeloma Studies KEYNOTE-183 and 185 of KEYTRUDA® (pembrolizumab) in Combination with Other Therapies
13 Jun 2017 Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma
13 Jun 2017 Numab and Kaken Pharmaceutical Co., Ltd. Enter into a Collaboration and Option Agreement

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top